InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
12
Disclosed sells
0
T+90 hit rate
44%
T+90 mean return
-2.5%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Shukla Sanjay, Chief Executive Officer. Insider active across 2 companies, notably aTYR PHARMA INC. In total, 15 filings have been recorded. Breakdown: 12 buys · 0 sell. Total volume traded: €291k. Activity tracked since 18 May 2021. The latest transaction was disclosed on 31 May 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
10,375 sharesCommon StockSEC:0000950170-25-013891:0
20,000 shares@ US$1.80713.8% of flowCommon StockSEC:0000950170-24-067666:0
Ideal exit: 25 Feb 2025 (T+270)
10,375 sharesCommon stockSEC:0001209191-24-002949:0
3,000 shares@ US$1.171.3% of flowCommon StockSEC:0001209191-23-058377:0
Ideal exit: 6 Sept 2024 (T+270)
1,422 shares@ US$1.1380.6% of flowCommon StockSEC:0001209191-23-054976:0
Ideal exit: 6 Aug 2024 (T+270)
15,000 shares@ US$2.014911.4% of flowCommon StockSEC:0001209191-23-043943:0
Ideal exit: 23 Apr 2024 (T+270)
10,375 sharesCommon stockSEC:0001209191-23-007362:0
10,000 shares@ US$2.14058.6% of flowCommon StockSEC:0001209191-22-058295:0
Ideal exit: 18 Aug 2023 (T+270)
15,000 shares@ US$2.877617.0% of flowCommon StockSEC:0001209191-22-041230:0
Ideal exit: 28 Mar 2023 (T+270)
5,000 shares@ US$6.761361.5% of flowCommon StockSEC:0001209191-22-002768
Ideal exit: 4 Oct 2022 (T+270)
5,000 shares@ US$6.76130.039% mcap26.2% of flowCommon StockSEC:0001209191-22-002768:0
Ideal exit: 4 Oct 2022 (T+270)
2,500 shares@ US$8.5750.024% mcap16.4% of flowCommon StockSEC:0001209191-21-064565:0
Ideal exit: 12 Aug 2022 (T+270)
2,500 shares@ US$8.57538.5% of flowCommon StockSEC:0001209191-21-064565
Ideal exit: 12 Aug 2022 (T+270)
10,000 shares@ US$4.010.043% mcap28.7% of flowCommon StockSEC:0001209191-21-034292:0
Ideal exit: 12 Feb 2022 (T+270)
10,000 shares@ US$4.0128.7% of flowCommon StockSEC:0001209191-21-034292
Ideal exit: 12 Feb 2022 (T+270)
15 of 15 declarations
About Shukla Sanjay
Sanjay Shukla is the President and CEO of aTYR PHARMA INC. He is responsible for the strategic direction of the company, focusing on innovation in the pharmaceutical sector. His leadership is essential for achieving growth and profitability objectives.
